A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers

Status Completed

Clinical Trial Summary

In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase). The study was amended and now includes patients with ocular surface inflammation.

Clinical Trial Description

In this prospective, single-centre, double blind (within each cohort), placebo controlled, randomised study, safety and tolerability of PP-001 eye drops is assessed in healthy, adult volunteers (cohorts 1-3) and in patients with ocular surface inflammation (cohort 4). PP-001 is a novel small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with anti-inflammatory properties. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03769454
Study type	Interventional
Source	Panoptes Pharma GmbH
Contact
Status	Completed
Phase	Phase 1
Start date	November 20, 2018
Completion date	March 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04067973` - Impact of Prematurity on the Optic Nerve
Completed	`NCT04828057` - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Not yet recruiting	`NCT06375343` - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®	Phase 1
Completed	`NCT00346450` - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation	Phase 3
Completed	`NCT04351100` - Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
Completed	`NCT03659955` - Autologous Blood Treatment for Ocular Surface Disease	N/A
Completed	`NCT04536129` - Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure	N/A
Completed	`NCT01254370` - Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease	Phase 2
Completed	`NCT00554411` - Assessing Ocular Surface Changes After Changing Glaucoma Medications	N/A
Recruiting	`NCT06256770` - Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia
Completed	`NCT04673604` - From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy	N/A
Not yet recruiting	`NCT06370585` - Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF	Phase 1
Withdrawn	`NCT04735510` - Novel Use of Restasis and PROSE Devices	Phase 3
Suspended	`NCT00348114` - Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency	Phase 2
Recruiting	`NCT04010422` - Ocular Function in Autism Spectrum Disorder
Completed	`NCT05528016` - Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty	N/A
Completed	`NCT04452279` - Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification	N/A
Completed	`NCT04535388` - LK Scleral Lens for Patients With Intractable Ocular Surface Diseases	N/A
Recruiting	`NCT06298890` - The Pattern of Dry Eye Disease After Cataract Surgery
Completed	`NCT02802137` - 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy	Phase 4